Radiation

New SWaP Optimized Nuclear Event Detector Provides 4X Greater Sensitivity and Added Functionality

Retrieved on: 
Monday, April 8, 2024
PIN, Radiation, ASIC, Scottish Government, Swap, Electronics, Engineering, ARO, Safety, NED, Soil, Medical imaging

Applications include missiles, satellites, ground vehicles, or any system which needs to potentially survive a nuclear event.

Key Points: 
  • Applications include missiles, satellites, ground vehicles, or any system which needs to potentially survive a nuclear event.
  • This new Nuclear Event Detector IC is manufactured on US soil in the Jazz Semiconductor Trusted Foundry, Inc. (JSTF), a wholly owned subsidiary of Tower Semiconductor NPB.
  • Customized NEDs can be optimized for the fastest response time, highest sensitivity, broadest dynamic range, reduced size and weight, or the most optimal combination of these features to address your specific requirements.
  • "These new NEDs provide greater safety and security in the protection of critical electronics subjected to a nuclear event, as they are able to recognize events with much greater sensitivity and react much faster to protect electronics than the current decades old NED devices."

Pomerantz Law Firm Announces the Filing of a Class Action Against Checkpoint Therapeutics, Inc. and Certain Officers - CKPT

Retrieved on: 
Saturday, April 6, 2024
Radiation, Biologics license application, District court, Patient, Defendant, CRL, News, Ext, Acquisition, LLP, Complaint, Pomerantz, CMO, Action Replay, Food, FDA, BLA, Court, Person

NEW YORK, April 5, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Checkpoint Therapeutics, Inc. ("Checkpoint" or the "Company") (NASDAQ: CKPT) and certain officers.

Key Points: 
  • NEW YORK, April 5, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Checkpoint Therapeutics, Inc. ("Checkpoint" or the "Company") (NASDAQ: CKPT) and certain officers.
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Orphan designation: Nirogacestat Treatment of soft tissue sarcoma, 17/10/2019 Positive

Retrieved on: 
Tuesday, April 9, 2024
Eurostat, Diagnosis, Civil service commission, Plantar fibromatosis, Radiation, Gene, Growth, Sarcoma, Blood, Disease, Patient, Committee, Knowledge, Tissue, Regulation, Cancer, EMA, IRIS, Radiation therapy, European, Therapy, COMP, Aggressive fibromatosis, Safety, European Commission, GS, Pain, Marketing, Swelling, Medicine, Pharmaceutical industry

Orphan designation: Nirogacestat Treatment of soft tissue sarcoma, 17/10/2019 Positive

Key Points: 


Orphan designation: Nirogacestat Treatment of soft tissue sarcoma, 17/10/2019 Positive

Orphan designation: Florilglutamic acid (18F) Diagnosis of hepatocellular carcinoma, 21/03/2016 Withdrawn

Retrieved on: 
Tuesday, April 9, 2024
Eurostat, Diagnosis, Civil service commission, Radiation, MRI, Weakness, Cell, Hepatitis B, Disease, Infection, Magnetic resonance imaging, Cirrhosis, Patient, Committee, Weight loss, Knowledge, PET, Neoplasm, Abdomen, Tissue, Regulation, Cancer, EMA, IRIS, Hepatocellular carcinoma, Woman, Nausea, European, COMP, Sponsor, European Commission, Safety, Pain, Molecular imaging, Marketing, Swelling, Liver, Medicine, Pharmaceutical industry

Orphan designation: Florilglutamic acid (18F) Diagnosis of hepatocellular carcinoma, 21/03/2016 Withdrawn

Key Points: 


Orphan designation: Florilglutamic acid (18F) Diagnosis of hepatocellular carcinoma, 21/03/2016 Withdrawn

Orphan designation: Florilglutamic acid (18F) Diagnosis of glioma, 21/03/2016 Withdrawn

Retrieved on: 
Tuesday, April 9, 2024
Eurostat, Diagnosis, Civil service commission, Radiation, Personality, Brain, Headache, MRI, 18F, Aminolevulinic acid, Cell, Survival, Disease, Seizure, Magnetic resonance imaging, Patient, Committee, Knowledge, Glioma, PET, Tissue, Regulation, Cancer, FDOPA, EMA, IRIS, Nausea, European, Fluorodeoxyglucose (18F), COMP, Somatic symptom disorder, Sponsor, European Commission, Safety, Vomiting, Marketing, Hepatocellular carcinoma, Molecular imaging, Medicine, Pharmaceutical industry

Orphan designation: Florilglutamic acid (18F) Diagnosis of glioma, 21/03/2016 Withdrawn

Key Points: 


Orphan designation: Florilglutamic acid (18F) Diagnosis of glioma, 21/03/2016 Withdrawn

Orphan designation: Eflornithine Treatment of neuroblastoma, 27/09/2011 Withdrawn

Retrieved on: 
Tuesday, April 9, 2024
Eurostat, Diagnosis, Civil service commission, Radiation, Brain, Ornithine decarboxylase, Enzyme, Growth, Weakness, Survival, Cell, Neuroblastoma, Disease, Patient, Tablet, Committee, Knowledge, Abdomen, Regulation, Child, Cancer, EMA, IRIS, Bone pain, Mouth, European, Polyamine, Fever, COMP, Sponsor, European Commission, Spine, Safety, Marketing, Limited, Medicine, Pharmaceutical industry

Orphan designation: Eflornithine Treatment of neuroblastoma, 27/09/2011 Withdrawn

Key Points: 


Orphan designation: Eflornithine Treatment of neuroblastoma, 27/09/2011 Withdrawn

BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer

Retrieved on: 
Monday, March 25, 2024
IIT, Radiation, IO, Carcinoma, Survival, NSCLC, Entrepreneurship, Monroe Dunaway Anderson, Patient, Journal, Merck, Overalls, MD, Lung, Neoplasm, Safety, EP, SITC, PFS, PD-L1, Platinum, Horn, Immunotherapy, PD-1, Medical imaging

This Phase 2 trial will evaluate the efficacy and safety of Pembrolizumab, Plinabulin plus EP in 1L ES-SCLC.

Key Points: 
  • This Phase 2 trial will evaluate the efficacy and safety of Pembrolizumab, Plinabulin plus EP in 1L ES-SCLC.
  • KEYNOTE-604 study revealed that 12-month PFS rate in patients with pembrolizumab plus EP is 13.6% vs. 3.1% with placebo plus EP.
  • Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell Lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
  • An Open-Label, Single-Arm, Phase II Study of Pembrolizumab, Plinabulin Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer.

RocketStar Announces Successful Demonstration of Fusion-Enhanced Pulsed Plasma Electric Propulsion

Retrieved on: 
Wednesday, March 20, 2024
Nuclear fusion, Radiation, USSF, Plasma, Georgia Tech, Boron, Proton, SBIR, University, Spacecraft, OTV, Carbon, AFWERX, Nuclear engineering, Alpha, Firestar, Gamma, SpaceX, ION Satellite Carrier, Lithium

NEW YORK, March 20, 2024 (GLOBE NEWSWIRE) -- RocketStar Inc. has successfully demonstrated the FireStar Drive, a groundbreaking electric propulsion unit for spacecraft that uses nuclear fusion-enhanced pulsed plasma.

Key Points: 
  • NEW YORK, March 20, 2024 (GLOBE NEWSWIRE) -- RocketStar Inc. has successfully demonstrated the FireStar Drive, a groundbreaking electric propulsion unit for spacecraft that uses nuclear fusion-enhanced pulsed plasma.
  • This innovative device significantly boosts the performance of RocketStar's base water-fueled pulsed plasma thruster by utilizing a unique form of aneutronic nuclear fusion.
  • The fusion discovery was first made during an SBIR Phase 1 for AFWERX where boronated water was introduced into the pulsed plasma thruster’s exhaust plume.
  • “We are very excited to test FireStar for RocketStar,” said Brent Abbott, CRO at Rogue Space Systems.

Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network

Retrieved on: 
Tuesday, March 19, 2024
Macular edema, Fluocinolone acetonide, Observation, Intravitreal implants, Injection, Risk, Paratriathlon, Patient, Alimera Sciences, Plaque, Cleveland Clinic, Retina, Brachytherapy, Radiation, Physician

ATLANTA, March 19, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that the first patient has been randomized in the DRCR Retina Network’s Protocol AL. The study is titled, “A Randomized Clinical Trial Evaluating Intravitreal Faricimab (6.0 mg) Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of Visual Acuity Loss due to Radiation Retinopathy.”

Key Points: 
  • ATLANTA, March 19, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that the first patient has been randomized in the DRCR Retina Network’s Protocol AL.
  • The study is titled, “A Randomized Clinical Trial Evaluating Intravitreal Faricimab (6.0 mg) Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of Visual Acuity Loss due to Radiation Retinopathy.”
    The study, chaired by Arun Singh, M.D.
  • (Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio), plans to include 600 participants with primary choroidal melanoma receiving treatment with plaque brachytherapy.
  • “We are very excited that this study is underway as it has the potential to show ILUVIEN addressing another unmet need affecting the retina,” said Rick Eiswirth, President and Chief Executive Officer of Alimera.

QDOSE® Platform Partnership for Personalized Dosimetry in Radiopharmaceutical Therapy

Retrieved on: 
Monday, March 18, 2024
Radiation, CE, Artificial intelligence, ASX, European, TLX, FDA, Medical imaging

QDOSE® is a validated, versatile software platform that enables reliable estimation of patient-specific dosimetry for both therapeutic and diagnostic radiopharmaceuticals.

Key Points: 
  • QDOSE® is a validated, versatile software platform that enables reliable estimation of patient-specific dosimetry for both therapeutic and diagnostic radiopharmaceuticals.
  • Telix intends to integrate the QDOSE® platform into its therapeutic radiopharmaceutical programs and clinical collaborations to enable the development of personalized treatment regimens.
  • Personalized radiopharmaceutical therapy administration based on individual patient dosimetry has the potential to improve clinical outcomes by optimizing treatment response while reducing effects on normal healthy organs and optimizing the use of isotope supply chains.
  • Rapid, reliable and personalized dosimetry is becoming an increasingly important future direction of cancer care and regulatory authorities now expect to see dosimetry analysis.